news

CUPERTINO, Calif., April 16, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational product POSIDUR (SABER®-Bupivacaine).  POSIDUR is a post-operative pain relief depot that utilizes DURECT‘s patented SABER technology to deliver bupivacaine and is designed to provide […]

CUPERTINO, Calif., Feb. 28, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended December 31, 2012. Total revenues were $3.3 million for the three months ended December 31, 2012 as compared to $8.9 million for the three months ended December 31, 2011.  Net loss was $5.5 million for the

CUPERTINO, Calif., Feb. 22, 2013 /PRNewswire/ — In conjunction with DURECT Corporation‘s (Nasdaq: DRRX) fourth quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, February 28, 2013 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live

CUPERTINO, Calif., Feb. 5, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  Matthew J. Hogan, Chief Financial Officer, will present at the BIO CEO & Investor Conference on Tuesday, February 12 at 11:00 a.m. Eastern time.  The conference is being held at the Waldorf-Astoria

CUPERTINO, Calif., Jan. 3, 2013 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced that its licensee, Zogenix Inc. (Nasdaq: ZGNX), today reported positive single-dose pharmacokinetic (PK) results from the Phase 1 clinical trial of Relday™, an investigational candidate of a proprietary, once-monthly subcutaneous formulation of risperidone for the treatment of schizophrenia.  According to Zogenix, adverse events

CUPERTINO, Calif., Dec. 6, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the pricing of an underwritten public offering of 14 million shares of its common stock, offered at a price of $0.90 per share to the public.  The gross proceeds to DURECT from this offering are expected to be approximately $12.6 million, before deducting

CUPERTINO, Calif., Nov. 13, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  James E. Brown, President and CEO, will present at the Credit Suisse 2012 Healthcare Conference on Thursday, November 15 at 10:00 a.m. Mountain Time (12:00 Noon Eastern).  The conference is being

CUPERTINO, Calif., Nov. 5, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2012. Total revenues were $3.8 million for the three months ended September 30, 2012 as compared to $8.1 million for the three months ended September 30, 2011.  Net loss for the three months ended

CUPERTINO, Calif., Oct. 30, 2012 /PRNewswire/ — In conjunction with DURECT Corporation‘s (Nasdaq: DRRX) third quarter 2012 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, November 5, 2012 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A

CUPERTINO, Calif., Aug. 21, 2012 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.  (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) Matt Hogan, Chief Financial Officer, will present at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5 at 3:15 p.m. Eastern Time.  The conference is being held at the Four